In contrast to in vitro tumor cell growth, when KPL-4, SKOV3, and 3T3-HER2 cells were implanted into SCID-beige mice and treated in vivo, we consistently observed enhanced therapeutic efficacy with the combination therapy (T+P) compared with the monotherapy of each HER2 mAb (Figure 1, B–D). This evidence concerns the gene ERBB2 and neoplasm.